{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The impact of PEGASYS on JAK2 will be measured by the allele burden; hematopoietic cell clonality will be measured by whether patients with clonal disease return to polyclonal; bone marrow histopathology will be measured by going from abnormal to normal; cytogenetic abnormalities will be measured by seeing if the cytogenetics go from abnormal to normal.To compare the impact of therapy on JAK2-V617F (JAK2), CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.","groups":[{"description":"The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG000","title":"PEGASYS"},{"description":"Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG001","title":"Hydroxyurea"}],"populationDescription":"data not collected","reportingStatus":"POSTED","timeFrame":"4 years","title":"Allele Burden","type":"SECONDARY"}